Endometrial Rejuvenation Study (NCT04045821) | Clinical Trial Compass
TerminatedNot Applicable
Endometrial Rejuvenation Study
Stopped: low enrollment
United States3 participantsStarted 2020-01-17
Plain-language summary
To evaluate the response of the endometrial lining after subcutaneous administration of the medication AMD3100. This medication mobilizes stem cells and will be used in a population of infertile women with a thin endometrium who are undergoing frozen-thawed embryo transfer. The investigators will assess associations between response to stem cell mobilization and pregnancy outcomes.
Who can participate
Age range18 Years – 55 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients planning to undergo a frozen-thawed embryo transfer cycle using a single euploid blastocyst.
✓. Patients who have previously undergone at least 2 unsuccessful frozen-thawed embryo transfer cycles, defined as failure to achieve a clinical pregnancy (visualization of intrauterine gestational sac on ultrasound) or a cancelled embryo transfer cycle due to inadequate endometrial thickness.
✓. Patients with a diagnosis of thin endometrial lining (less than 6 mm maximum thickness) during at least one prior unsuccessful embryo transfer cycle.
✓. Initiation of the most recent unsuccessful frozen-thawed embryo transfer cycle with a thin endometrial lining must have occurred after January 1, 2017.
Exclusion criteria
✕. Fewer than 2 prior unsuccessful frozen-thawed embryo transfer cycles.
✕. Most recent unsuccessful frozen-thawed embryo transfer prior to January 1, 2017.